Sign inJoin waitlistJoin the waitlist

Paul Unger

Interim Medical Director, Solid Tumor Oncology, UVM Health • Hematologist and Medical Oncologist, UVM Health · Robert Larner College of Medicine

Credentials: · · · · · ·

History

Solid Tumor Oncology · Robert Larner College of Medicine
Present
Robert Larner College of Medicine
Present

Dana-Farber Cancer Institute
1992–1994
Brigham and Women's Hospital
1990–1992
New York Presbyterian Hospital
1987–1990
Wesleyan University, Middletown
1986–1987
Harvard Medical School
1982–1986
Wesleyan University, Middletown
1978–1982

Research

Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer
Journal of Clinical Oncology · 2002 · 261 citations
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone…
Systematic review or meta-analysis · Journal of Clinical Oncology · 2021 · 60 citations
Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34+ cell content
Bone Marrow Transplantation · 1997 · 52 citations

KB
Kamal Bakri
2 papers
MS
Mark Socinski
2 papers
MK
Merrill Kies
2 papers
AH
Alan Houghton
1 paper
AA
Avan Armaghani
1 paper
Beverly Moy
1 paper
Claire Verschraegen
1 paper
DA
Deborah Abrams
1 paper
Douglas Yee
1 paper
FK
Farrah Khan
1 paper
Gabriel Hortobagyi
1 paper
Heather McArthur
1 paper

Clinical trials

Evaluation of Loratadine for Prevention of Pegfilgrastim-Induced Pain
Sub-investigator · Unknown · Phase 2
University of Vermont
2011–2013
Neoadjuvant Cisplatin/Docetaxel (CDDP/TXT) and Chemoradiation for Head and Neck Cancer
Sub-investigator · Unknown · Phase 1, Phase 2
University of Vermont
2009–2012